Anti-CD3-activated killer T cells: Interleukin-6 modulates the induction of major histocompatibility complex-unrestricted cytotoxicity and the expression of genes coding for cytotoxic effector molecules

被引:9
作者
Greene, AL [1 ]
Makrigiannis, AP [1 ]
Fitzpatrick, L [1 ]
Hoskin, DW [1 ]
机构
[1] Dalhousie Univ, Fac Med, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada
关键词
D O I
10.1089/jir.1997.17.727
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have investigated the role of interleukin-6 (IL-6) in the induction of major histocompatibility complex (MHC)-unrestricted cytotoxicity, as well as granzyme B, perforin, and Fas ligand gene expression, following mouse T lymphocyte activation with anti-CD3 monoclonal antibody (mAb), The generation of anti-CD3-activated killer-T (AK-T) cells was inhibited when anti-IL-6 neutralizing mAb was added at initiation of culture but not 24 h later, indicating that IL-6 is involved at an early stage of AK-T cell development, However, AK-T cell induction in the presence of exogenous IL-6 did not result in enhanced cytotoxicity, suggesting that saturating levels of IL-6 are normally synthesized in AK-T cell cultures, The inhibitory effect of IL-6 neutralization on AK-T cell generation could not be attributed to a defect in AK-T cell proliferation or to an inability of AK-T cells to recognize and adhere to P815 tumor target cells, However, IL-2 synthesis and CD25 expression were downregulated in AK-T cell cultures performed in the presence of anti-IL-6 mAb, In addition, IL-6 neutralization resulted in decreased expression of granzyme B and perforin, but not Fas ligand, mRNA, Exogenous IL-2 (50 U/ml) added at initiation of culture completely reversed the inhibitory effect of anti-IL-6 mAb on AK-T cell development, restoring CD25 expression and tumoricidal activity, as well as granzyme B and perforin mRNA expression, to control levels, We conclude that IL-6 modulates AK T cell induction through an IL-2-dependent mechanism.
引用
收藏
页码:727 / 737
页数:11
相关论文
共 48 条
[41]   IMMUNOTHERAPY OF PATIENTS WITH ADVANCED CANCER USING TUMOR-INFILTRATING LYMPHOCYTES AND RECOMBINANT INTERLEUKIN-2 - A PILOT-STUDY [J].
TOPALIAN, SL ;
SOLOMON, D ;
AVIS, FP ;
CHANG, AE ;
FREERKSEN, DL ;
LINEHAN, WM ;
LOTZE, MT ;
ROBERTSON, CN ;
SEIPP, CA ;
SIMON, P ;
SIMPSON, CG ;
ROSENBERG, SA .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) :839-853
[42]   PRECLINICAL STUDIES USING IMMOBILIZED OKT3 TO ACTIVATE HUMAN T-CELLS FOR ADOPTIVE IMMUNOTHERAPY - OPTIMAL CONDITIONS FOR THE PROLIFERATION AND INDUCTION OF NON-MHC-RESTRICTED CYTOTOXICITY [J].
UBERTI, JP ;
JOSHI, I ;
UEDA, M ;
MARTILOTTI, F ;
SENSENBRENNER, LL ;
LUM, LG .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1994, 70 (03) :234-240
[43]  
VANDAMME J, 1988, J IMMUNOL, V140, P1534
[44]   ACCESSORY FACTORS INVOLVED IN MURINE T-CELL ACTIVATION - DISTINCT ROLES OF INTERLEUKIN-6, INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR [J].
VINK, A ;
UYTTENHOVE, C ;
WAUTERS, P ;
VANSNICK, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1990, 20 (01) :1-6
[45]  
WATANABE H, 1992, ANTICANCER RES, V12, P1925
[46]  
WHITESIDE TL, 1990, IMMUNOL ALLERGY CLIN, V10, P663
[47]   USE OF ANTI-CD3 MONOCLONAL-ANTIBODY IN THE GENERATION OF EFFECTOR-CELLS FROM HUMAN SOLID TUMORS FOR USE IN CANCER BIOTHERAPY [J].
YANNELLI, JR ;
CRUMPACKER, DB ;
GOOD, RW ;
FRIDDELL, CD ;
POSTON, R ;
HORTON, S ;
MALECKAR, JR ;
OLDHAM, RK .
JOURNAL OF IMMUNOLOGICAL METHODS, 1990, 130 (01) :91-100
[48]   ACTIVATION BY ANTI-CD3 OF TUMOR-DRAINING LYMPH-NODE CELLS FOR SPECIFIC ADOPTIVE IMMUNOTHERAPY [J].
YOSHIZAWA, H ;
SAKAI, K ;
CHANG, AE ;
SHU, SY .
CELLULAR IMMUNOLOGY, 1991, 134 (02) :473-479